Replimune
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer.
REPL Key Statistics
Stock Snapshot
Replimune(REPL) stock is priced at $2.26, giving the company a market capitalization of 186.61M. It carries a P/E multiple of -0.54.
On 2026-04-15, Replimune(REPL) stock traded between a low of $1.88 and a high of $2.30. Shares are currently priced at $2.26, which is +20.2% above the low and -1.7% below the high.
Replimune(REPL) shares are trading with a volume of 11.41M, against a daily average of 12.44M.
In the last year, Replimune(REPL) shares hit a 52-week high of $13.24 and a 52-week low of $1.50.
In the last year, Replimune(REPL) shares hit a 52-week high of $13.24 and a 52-week low of $1.50.
REPL News
Replimune Group, Inc. recently received a complete response letter from the FDA rejecting its Biologics License Application for RP1 plus nivolumab in advanced m...
Biotech and Pharma Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. In this article REPL BMY Replimune Group said it was p...
Wedbush downgraded Replimune (REPL) to Neutral from Outperform with a price target of $2, down from $19, after the FDA issued a second complete response letter...
Analyst ratings
50%
of 8 ratingsMore REPL News
Replimune (REPL) Group announced that the company received a complete response letter from the U.S. Food and Drug Administration for the Company’s Biologics Lic...
Cantor Fitzgerald downgraded Replimune (REPL) to Neutral from Overweight. Published first on TheFly – the ultimate source for real-time, market-moving breaking...
In a Complete Response Letter addressed to Replimune (REPL) dated April 10 posted to the site of the FDA, the agency stated: “We have completed a comprehensive...
This move comes following a report detailing the FDA’s acceptance of the resubmission of the Biologics License Application for RP1 in combination with nivolumab...
Replimune Group (NASDAQ:REPL) shares are down on Thursday. The company faces an upcoming FDA review decision on Friday, 10 April. Replimmune RP1 Filing Faces Re...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.